Meet the latest global health tech startups to get an invite to Houston from TMC Innovation. Photo via tmc.edu

The Texas Medical Center's innovation arm has again invited a set of health tech startups to mix and mingle with potential partners, investors, and customers in hopes to score a place in the HealthTech Accelerator.

For the 17th time, the TMC Innovation Factory is hosting its HealthTech Accelerator — starting first with announcing its bootcamp cohort, a process that includes bringing all 10 companies to Houston for valuable networking. A selection of the bootcamp will be invited into the full accelerator that will run into next spring.

The 10 selected companies with solutions from heart failure to chronic respiratory disease and more, according to TMC, include:

  • Acorai, from Stockholm, Sweden, which is developing a first-of-its-kind, hand-held, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 64 million patients worldwide.
  • Singapore-based Aevice Health, a connected care platform powered by the world’s smallest smart wearable stethoscope to support chronic respiratory disease patients through their continuum of care.
  • AirSeal, based in St. Louis, Missouri, which has developed a novel serum-based biomarker technology – circulating fatty acid synthase (cFAS) – that can diagnose cardiovascular and peripheral artery disease with high accuracy in both women and men.
  • Candlelit Care, a Charlotte, North Carolina-based point-of-care digital platform focused on the prevention of perinatal mental and anxiety disorders (PMADs) among Black women and birthing parents.
  • San Francisco-based Knowtex, an artificial intelligence-powered software writes medical documentation for you and assigns correct codes to ensure proper reimbursement.
  • NeuroBell, from Cork, Ireland, which is working on a novel medical device providing portable EEG monitoring with real-time and automated neonatal seizure alerts at the bedside.
  • Perth, Australia-based OncoRes Medical that's developing an intraoperative imaging technology to provide surgeons with real-time assessment of tissue microstructure.
  • From right here in Houston, Steradian Technologies, which has created RUMI, the first noninvasive, fully portable infectious disease diagnostic that costs the price of a latte. It uses novel photon-based detection to collect and diagnose infectious diseases in breath within 30 seconds.
  • Foxo, headquartered in Brisbane, Australia, serves as an interoperable tool designed to enhance clinical collaboration across the healthcare ecosystem. It enables secure, two-way communication with features such as video, voice, screen share, file sharing, and real-time messaging.
  • Thrive Health’s, from Vancouver, Canada, is a platform is a low-code framework for designing and delivering patient engagement solutions. Create tools that enable partners to close healthcare gaps quickly, strengthen care relationships, and improve patient experience and outcomes.

TMC Innovation's last bootcamp cohort was announced in May. The organization also recently named 16 digital health and medical device startups from the United Kingdom to a new accelerator formed in partnership with Innovate UK.

Earlier this fall, TMC formed a strategic partnership, or BioBridge, with the Netherlands.

Innovative shoewear, luxury EV charging, and more — all this innovation and more is coming out of Houston startups. Courtesy photos

Top 5 Houston startup feature stories of 2022

year in review

Editor's note: As 2022 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. This past year, InnovationMap featured profiles on dozens of these Houston startups — from sportstech apps and health tech companies to startups with solutions in EV tech and more. Here are five Houston startup features that stood out to readers this year — be sure to click through to read the full story.

Houston-based health tech startup is revolutionizing patient selection for clinical trials

Sieve Health is an AI cloud-based SaaS platform designed to automate and accelerate matching patients with clinical trials. Photo via Getty Images

On many occasions in her early career, Dr. Arti Bhosale, co-founder and CEO of Sieve Health, found herself frustrated with having to manually sift through thousands of digital files.

The documents, each containing the medical records of a patient seeking advanced treatment through a clinical trial, were always there to review — and there were always more to read.

Despite the tediousness of prescreening, which could take years, the idea of missing a patient and not giving them the opportunity to go through a potentially life-altering trial is what kept her going. The one she didn’t read could have slipped through the cracks and potentially not given someone care they needed.

“Those stories have stayed with me,” she says. “That’s why we developed Sieve.” Read more.

Houston startup snags prestigious grant from global health leader

Houston-based medical device and biotech startup Steradian Technologies has been recognized by the Bill and Melinda Gates Foundation. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

A female-founded biotech startup has announced that it has received a grant from the Bill & Melinda Gates Foundation.

Steradian Technologies has developed a breath-based collection device that can be used with diagnostic testing systems. Called RUMI, the device is non-invasive and fully portable and, according to a news release, costs the price of a latte.

“We are extremely honored to receive this award and be recognized by the Bill & Melinda Gates Foundation, a leader in global health. This funding will propel our work in creating deep-tech diagnostics and products to close the equity gap in global public health," says Asma Mirza, CEO and co-founder of Steradian Technologies, in the release. “The RUMI will demonstrate that advanced technology can be delivered to all areas of the world, ensuring the Global South and economically exploited regions receive access to high-fidelity diagnostics instead of solutions that are ill-suited to the environment.” Read more.

Houston sports tech startup is enhancing performance metrics for runners and athletes

Houston-based AiKYNETIX is equipping runners with high-tech tracking tools. Image courtesy of AiKYNETIX

With the Houston Marathon only five months away, a new application using human motion insights could help a runner refine their form to reach peak performance – all from the convenience of their smart phone.

While traditional treadmills are limited in training feedback and wearables are not designed to track elevation, Houston-based AiKYNETIX uses real-time technology to provide a new option for runners on treadmills.

“Runners spend a lot of time, energy and money to run better,” says Denis Akhiyarov, CEO and co-founder. “In my personal life with training for nine marathons, I’ve seen limitations with wearables, they don’t actually track running form while running. Overall, our technology tracks not only your basic parameters but it can also analyze the human running form while in motion.” Read more.

Local startup to upgrade EV charging in Houston and beyond

Houston-based Spark Spaces is looking to build out luxury spots for electric vehicle charging. Rendering courtesy of Spark Spaces

At 3 a.m. one night, just as he had many nights before, Tarun Girish found himself leaving his Houston apartment in search of an EV charger.

Once he located one, he would sit in his car for an hour and a half while his vehicle charged — with not much to do but wait.

But it was on this night he wondered if there was a way to use his previous hospitality experience to build a new kind of experience for EV drivers. He then developed his first iteration of a business plan — all while sitting in his driver’s seat.

His idea became Sparks Spaces, a startup formed in 2021 looking to shake up the EV charging game — the company aims to elevate the experience of charging electric vehicles by focusing on the space between car and charger by creating an airport lounge-type space for drivers. These EV lounges would include luxury waiting areas, clean restrooms, high-end food options, and availability to utilize them 24/7. Read more.

Houston neuroscientist turned startup founder takes steps toward comfier shoes

Steffie Tomson founded a company to prioritize comfort — without sacrificing style — for women on the go. Photo via getawaysticks.com

Two and half years ago, native Houstonian Steffie Tomson ordered $2,000 worth of shoes and sliced them all in half with a bandsaw just to see what was inside.

Tomson, a neuroscientist by trade and the founder and CEO of footwear startup Getaway Sticks, had an idea for a different kind of shoe — one that was redesigned to prioritize women’s comfort.

“I thought, ‘why can’t we start with a sneaker material and then build a heel around it?’” she tells InnovationMap. “I started just slicing everyone else’s shoes and now I’m more convinced than ever that our shoe is different.” Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.